Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
This article was originally published in PharmAsia News
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan
You may also be interested in...
Daiichi Sankyo is teaming with virtual startup Coherus BioSciences for etanercept and rituximab.
Korea’s biosimilar frontrunner Celltrion is only one step away from the actual sales of its first biosimilar as it gears up to file for KFDA approval in February for its biosimilar of Johnson & Johnson’s rheumatoid arthritis agent Remicade.
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma